# SA1211 Injection Phase 1 Study

> **NCT07275918** · PHASE1 · RECRUITING · sponsor: **Suzhou Siran Biotechnology Co.,Ltd.** · enrollment: 80 (estimated)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** SA1211 injection
- **DRUG:** SA1211 injection placebo

## Key facts

- **NCT ID:** NCT07275918
- **Lead sponsor:** Suzhou Siran Biotechnology Co.,Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-25
- **Primary completion:** 2027-03-30
- **Final completion:** 2027-03-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-12-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07275918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07275918, "SA1211 Injection Phase 1 Study". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT07275918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*